XNAS · VBIO
-1.79% · -$0.0400 · Vol 57.6K
Market closed · last close 4:00 PM ET · price as of 19:39:00 ET
Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$2.19
Card
Relationship Map

Follow $VBIO

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $VBIO by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
No analyst covers this company · Sentiment absence reason unknown
VBIO
Valion Bio, Inc. Common Stock
Sun Sep 20 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Sun Sep 20 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is VBIO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading VBIO catalysts
About Valion Bio, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
52
Country
US

Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.29
Day high
$2.36
Day low
$2.12
Previous close
$2.23
52W high
$27.75
-92.11% from high
52W low
$2.08
0% of range
Market cap
$1.9M
EPS
$-2.1700
Beta
-1.30
Shares out
887.6K
Volume
57.6K
0.07× rel vol
Avg volume
795.9K
VWAP
$2.24
Price history computed in-house
1W
-3.10%
1M
-28.55%
3M
-82.95%
SMA 50 $5.73 · below
SMA 200 Not reported · Not reported
52W position 0%

VBIO overview

Veridion Score
59
Registered · 2026-09-18
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around VBIO.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading VBIO Form 4 filings
Public disclosures

Congress activity in VBIO

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for VBIO in the cached public ledger.

Federal contracts

VBIO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for VBIO in this window.
Lobbying spend

VBIO lobbying filings, year to date.

Registered lobbying filings matched to Valion Bio, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for VBIO in this window.
Loading news for VBIO
Analyst ratings
Sovereign unlock shows live analyst consensus for VBIO.
Options
Sovereign unlock shows live options positioning for VBIO.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.